Skip to main content
Premium Trial:

Request an Annual Quote

CAT Gains Access to Incyte s Database, Secures Rights to Develop Products

NEW YORK, Dec. 19 – Cambridge Antibody Technology of Melbourn, UK, has licensed access to Incyte’s LifeSeq Gold database and obtained options for the rights to develop products based on the data, the companies said Wednesday.

CAT will use the data as well as cDNA clones Incyte provides to develop antibody therapeutic products. CAT also has the right to gain the exclusive licences from Incyte develop treatments aimed at protein targets in Incyte’s database.

In exchange, CAT will pay a licence fee, plus milestones and royalties to Incyte. 

“CAT has already demonstrated the power of combining antibody phage display and genomics-based target discovery, and this agreement adds a significant new source of genomics-derived targets to fuel CAT's drug development pipeline," David Chiswell, CEO of CAT, said in a statement. 

CAT has developed technologies for to use human monoclonal antibodies for drug discovery and drug development. The company is currently running clinical trials for six of its therapeutic antibodies.

The company employs approximately 250 people.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.